Aastrom Biosciences, Inc. (ASTM) Granted Composition-Of-Matter Patent For Ixmyelocel-T In Australia
12/19/2013 9:04:29 AM
ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.
Help employers find you! Check out all the jobs and post your resume.
comments powered by